300206.SZ
Edan Instruments, Inc. [300206.SZ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
300206.SZ Stock Summary
Top 10 Correlated ETFs
300206.SZ
Top 10 Correlated Stocks
300206.SZ
In the News
300206.SZ Financial details
Company Rating
Neutral
Market Cap
5.8B
Income
221.3M
Revenue
1.94B
Book val./share
3.39
Cash/share
1.62
Dividend
0.21
Dividend %
2.12%
Employees
2.7K
Optionable
No
Shortable
Yes
Earnings
26 Apr 2024
P/E
20.22
Forward P/E
-
PEG
-53.21
P/S
2.76
P/B
2.86
P/C
5.62
P/FCF
31.31
Quick Ratio
5.52
Current Ratio
7.79
Debt / Equity
0.01
LT Debt / Equity
0.01
-
-
EPS (TTM)
0.38
EPS next Y
-
EPS next Q
-
EPS this Y
-5%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
10.56%
Revenue last 5Y
11.27%
Revenue Q/Q
-4.45%
EPS Q/Q
-151.94%
-
-
-
-
SMA20
-9.09%
SMA50
11.11%
SMA100
-9.09%
Inst Own
-
Inst Trans
-
ROA
13%
ROE
14%
ROC
0.15%
Gross Margin
58%
Oper. Margin
15%
Profit Margin
14%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
7.13-16.77
52W High
-43.13%
52W Low
+30%
RSI
39
Rel Volume
0.64
Avg Volume
11.21M
Volume
7.21M
Perf Week
-10.17%
Perf Month
-1.94%
Perf Quarter
-5.99%
Perf Half Y
-12.08%
-
-
-
-
Beta
0.193
-
-
Volatility
0.41%, 1.2%
Prev Close
-0.55%
Price
9.1
Change
-2.57%
300206.SZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.95 | 4 | 2.83 | 3.01 | 3.34 | |
| Net income per share | 0.23 | 1.13 | 0.4 | 0.4 | 0.38 | |
| Operating cash flow per share | 0.2 | 1.19 | 0.41 | 0.58 | 0.26 | |
| Free cash flow per share | 0.11 | 1.1 | 0.28 | 0.51 | 0.17 | |
| Cash per share | 0.8 | 1.82 | 1.44 | 1.65 | 1.62 | |
| Book value per share | 2.21 | 3.12 | 3 | 3.2 | 3.39 | |
| Tangible book value per share | 1.92 | 2.88 | 2.76 | 2.99 | 3.22 | |
| Share holders equity per share | 2.21 | 3.12 | 3 | 3.2 | 3.39 | |
| Interest debt per share | -0.05 | 0.19 | 0.13 | 0.02 | 0.03 | |
| Market cap | 4.21B | 10.59B | 8.14B | 6.97B | 5.92B | |
| Enterprise value | 3.89B | 9.93B | 7.48B | 6.03B | 5B | |
| P/E ratio | 31.93 | 16.21 | 35.15 | 29.94 | 26.77 | |
| Price to sales ratio | 3.71 | 4.57 | 4.97 | 4 | 3.06 | |
| POCF ratio | 36.52 | 15.35 | 34.29 | 20.81 | 39.24 | |
| PFCF ratio | 67.49 | 16.53 | 49.69 | 23.82 | 59.32 | |
| P/B Ratio | 3.26 | 5.85 | 4.7 | 3.76 | 3.01 | |
| PTB ratio | 3.26 | 5.85 | 4.7 | 3.76 | 3.01 | |
| EV to sales | 3.43 | 4.28 | 4.57 | 3.46 | 2.58 | |
| Enterprise value over EBITDA | 24.29 | 12.15 | 22.32 | 19.59 | 17.52 | |
| EV to operating cash flow | 33.78 | 14.4 | 31.51 | 17.98 | 33.12 | |
| EV to free cash flow | 62.44 | 15.5 | 45.66 | 20.59 | 50.07 | |
| Earnings yield | 0.03 | 0.06 | 0.03 | 0.03 | 0.04 | |
| Free cash flow yield | 0.01 | 0.06 | 0.02 | 0.04 | 0.02 | |
| Debt to equity | -0.02 | 0.06 | 0.04 | 0.01 | 0.01 | |
| Debt to assets | -0.02 | 0.05 | 0.04 | 0 | 0.01 | |
| Net debt to EBITDA | -1.97 | -0.8 | -1.97 | -3.08 | -3.24 | |
| Current ratio | 5.19 | 3.89 | 4.87 | 4.46 | 7.22 | |
| Interest coverage | 0 | 1.22K | 94.76 | 153.49 | 331.67 | |
| Income quality | 0.91 | 1.06 | 1.04 | 1.44 | 0.68 | |
| Dividend Yield | 0.01 | 0.01 | 0.03 | 0.02 | 0.02 | |
| Payout ratio | 0.45 | 0.16 | 1.09 | 0.52 | 0.54 | |
| Sales general and administrative to revenue | 0.03 | 0.01 | 0.02 | 0.02 | 0.02 | |
| Research and developement to revenue | 0.17 | 0.09 | 0.15 | 0.17 | 0.18 | |
| Intangibles to total assets | 0.12 | 0.06 | 0.07 | 0.05 | 0.04 | |
| Capex to operating cash flow | -0.46 | -0.07 | -0.31 | -0.13 | -0.34 | |
| Capex to revenue | -0.05 | -0.02 | -0.04 | -0.02 | -0.03 | |
| Capex to depreciation | -1.36 | -1.14 | -1.47 | -0.77 | -0.96 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 3.36 | 8.89 | 5.2 | 5.38 | 5.4 | |
| ROIC | 0.11 | 0.33 | 0.12 | 0.12 | 0.11 | |
| Return on tangible assets | 0.1 | 0.31 | 0.12 | 0.11 | 0.1 | |
| Graham Net | 0.85 | 1.63 | 1.43 | 1.6 | 1.79 | |
| Working capital | 683.76M | 1.21B | 1.1B | 1.23B | 1.34B | |
| Tangible asset value | 1.12B | 1.67B | 1.6B | 1.73B | 1.87B | |
| Net current asset value | 648.47M | 1.18B | 1.07B | 1.2B | 1.31B | |
| Invested capital | -0.02 | 0.06 | 0.04 | 0.01 | 0.01 | |
| Average receivables | 165.92M | 188.46M | 174.02M | 163.55M | 188.31M | |
| Average payables | 86.55M | 113.89M | 120.09M | 122.17M | 110.54M | |
| Average inventory | 179.42M | 277.25M | 376.94M | 414.1M | 415.2M | |
| Days sales outstanding | 55.14 | 32.31 | 31.85 | 38.61 | 36.22 | |
| Days payables outstanding | 73.78 | 49.1 | 57.54 | 62.6 | 39.92 | |
| Days of inventory on hand | 144.99 | 137.93 | 201.73 | 205.86 | 176.97 | |
| Receivables turnover | 6.62 | 11.3 | 11.46 | 9.45 | 10.08 | |
| Payables turnover | 4.95 | 7.43 | 6.34 | 5.83 | 9.14 | |
| Inventory turnover | 2.52 | 2.65 | 1.81 | 1.77 | 2.06 | |
| ROE | 0.1 | 0.36 | 0.13 | 0.13 | 0.11 | |
| Capex per share | -0.09 | -0.08 | -0.13 | -0.07 | -0.09 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.86 | 1.11 | 0.78 | 0.75 | 0.71 | |
| Net income per share | 0.07 | 0.24 | 0.11 | 0.05 | -0.03 | |
| Operating cash flow per share | 0.07 | 0.24 | 0 | 0.06 | 0.14 | |
| Free cash flow per share | 0.06 | 0.23 | -0.01 | 0.03 | 0.1 | |
| Cash per share | 1.65 | 1.7 | 1.49 | 1.53 | 1.62 | |
| Book value per share | 3.19 | 3.45 | 3.36 | 3.43 | 3.39 | |
| Tangible book value per share | 2.98 | 3.25 | 3.17 | 3.24 | 3.22 | |
| Share holders equity per share | 3.19 | 3.45 | 3.36 | 3.43 | 3.39 | |
| Interest debt per share | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | |
| Market cap | 6.99B | 7.57B | 8.74B | 6.35B | 5.92B | |
| Enterprise value | 6.05B | 6.6B | 8.09B | 5.88B | 5B | |
| P/E ratio | 40.42 | 13.48 | 32.79 | 53.26 | -95.27 | |
| Price to sales ratio | 13.97 | 11.83 | 19.41 | 14.63 | 14.3 | |
| POCF ratio | 161.68 | 53.91 | 3.33K | 197.1 | 74.51 | |
| PFCF ratio | 215.98 | 57.62 | -1.8K | 327.79 | 102.53 | |
| P/B Ratio | 3.77 | 3.8 | 4.49 | 3.2 | 3.01 | |
| PTB ratio | 3.77 | 3.8 | 4.49 | 3.2 | 3.01 | |
| EV to sales | 12.08 | 10.32 | 17.97 | 13.56 | 12.07 | |
| Enterprise value over EBITDA | 114.55 | 42.33 | 116.94 | 254.67 | -315.81 | |
| EV to operating cash flow | 139.79 | 47.01 | 3.08K | 182.7 | 62.89 | |
| EV to free cash flow | 186.74 | 50.25 | -1.67K | 303.84 | 86.54 | |
| Earnings yield | 0.01 | 0.02 | 0.01 | 0 | 0 | |
| Free cash flow yield | 0 | 0.02 | 0 | 0 | 0.01 | |
| Debt to equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Debt to assets | 0 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Net debt to EBITDA | -17.93 | -6.21 | -9.39 | -20.08 | 58.36 | |
| Current ratio | 4.46 | 5.63 | 7.48 | 7.79 | 7.22 | |
| Interest coverage | 85.05 | 1.77K | 355.5 | 138.63 | -166.48 | |
| Income quality | 1 | 1 | 0.04 | 1.08 | -5.11 | |
| Dividend Yield | 0 | 0 | 0.01 | 0 | 0.02 | |
| Payout ratio | 0 | 0 | 1.8 | 0 | -7.72 | |
| Sales general and administrative to revenue | -0.08 | 0.04 | -0.02 | 0.16 | -0.11 | |
| Research and developement to revenue | 0.19 | 0.12 | 0.17 | 0.19 | 0.26 | |
| Intangibles to total assets | 0.05 | 0.05 | 0.05 | 0.05 | 0.04 | |
| Capex to operating cash flow | -0.25 | -0.06 | -2.85 | -0.4 | -0.27 | |
| Capex to revenue | -0.02 | -0.01 | -0.02 | -0.03 | -0.05 | |
| Capex to depreciation | -0.81 | -0.66 | -0.55 | 0.5 | -1.57 | |
| Stock based compensation to revenue | 0.01 | 0 | 0 | 0 | 0 | |
| Graham number | 2.31 | 4.35 | 2.95 | 2 | 1.43 | |
| ROIC | 0.02 | 0.07 | 0.04 | 0.01 | -0.01 | |
| Return on tangible assets | 0.02 | 0.06 | 0.03 | 0.01 | -0.01 | |
| Graham Net | 1.59 | 1.82 | 1.74 | 1.79 | 1.79 | |
| Working capital | 1.23B | 1.37B | 1.32B | 1.36B | 1.34B | |
| Tangible asset value | 1.73B | 1.88B | 1.84B | 1.87B | 1.87B | |
| Net current asset value | 1.2B | 1.34B | 1.29B | 1.32B | 1.31B | |
| Invested capital | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Average receivables | 183.41M | 201.03M | 212.46M | 212.38M | 204.95M | |
| Average payables | 112.89M | 152.06M | 138.24M | 105.07M | 98.68M | |
| Average inventory | 435.72M | 448.98M | 458.95M | 446.6M | 421.87M | |
| Days sales outstanding | 33.13 | 30.63 | 41.41 | 45.16 | 41.77 | |
| Days payables outstanding | 56.47 | 57.98 | 49.35 | 52.01 | 44.3 | |
| Days of inventory on hand | 185.69 | 156.51 | 215.34 | 215.4 | 196.37 | |
| Receivables turnover | 2.72 | 2.94 | 2.17 | 1.99 | 2.15 | |
| Payables turnover | 1.59 | 1.55 | 1.82 | 1.73 | 2.03 | |
| Inventory turnover | 0.48 | 0.58 | 0.42 | 0.42 | 0.46 | |
| ROE | 0.02 | 0.07 | 0.03 | 0.02 | -0.01 | |
| Capex per share | -0.02 | -0.02 | -0.01 | -0.02 | -0.04 |
300206.SZ Frequently Asked Questions
What is Edan Instruments, Inc. stock symbol ?
Edan Instruments, Inc. is a CN stock and trading under the symbol 300206.SZ
What is Edan Instruments, Inc. stock quote today ?
Edan Instruments, Inc. stock price is $9.1 today.
Is Edan Instruments, Inc. stock public?
Yes, Edan Instruments, Inc. is a publicly traded company.
Company Profile
- Volume Average 11.21M
- Market Capitalization 5.8B
- Employee 2.7K
- CEO Mr. Hao Zhang
- Headquarters Shenzhen,CN
- IPO Date 2011-04-21
-
Website
https://www.edan.com 
Edan Instruments, Inc. engages in the research, development, manufacture, and sale of medical equipment worldwide. The company offers diagnostic electrocardiograph (ECG) products, including resting ECG, stress test, holter, wireless solution, and ECG workstation products; patient monitoring systems, such as vital signs, transport, and central monitoring systems, as well as high acuity cares, acute and sub-acute cares, telemetry, and pulse oximetry products; and obstetrics and gynecology products comprising fetal and maternal monitoring systems, fetal telemetry systems, ultrasonic doppler systems, and video colposcopes. It also provides ultrasound imaging systems that include color doppler ultrasound and B/W digital ultrasound systems; and in-vitro diagnostics, which comprise hematology analyzers. In addition, the company offers point-of-care testing systems, including blood gas and chemistry, magnetic immunoassay, and colloidal gold-labeled immunoassay analyzers; and veterinary ultrasound, ECG, ABG, and monitoring products. Edan Instruments, Inc. is headquartered in Shenzhen, the People's Republic of China.
